Investment Rating - The report assigns a "Buy" rating for the stock of YaoKang Bio (688046) based on its performance and growth potential [11]. Core Insights - YaoKang Bio has shown a quarterly acceleration in performance, with a revenue of 576 million yuan for the first three quarters of 2025, representing a year-on-year growth of 12.92%. The net profit attributable to the parent company reached 110 million yuan, up 11.90% year-on-year, and the non-recurring net profit was 93 million yuan, reflecting a significant increase of 29.21% [1][2]. - The functional efficacy business is identified as a key driver of growth, with a revenue of 87.93 million yuan in the first half of 2025, marking a year-on-year increase of 23.69%. New orders have surged by over 40% year-on-year, indicating strong demand [2]. - The establishment of a wholly-owned subsidiary, NiuMai Bio, aims to cultivate a fully human antibody platform, which is expected to become a significant growth engine for the company. The subsidiary has completed comprehensive validation of various human antibody models and is actively engaged in innovative antibody research across multiple therapeutic areas [3]. Financial Performance Summary - For the fiscal years 2025 to 2027, the projected revenues are 790 million yuan, 950 million yuan, and 1.144 billion yuan, respectively, with corresponding net profits of 143 million yuan, 177 million yuan, and 221 million yuan. The earnings per share (EPS) are expected to be 0.35 yuan, 0.43 yuan, and 0.54 yuan, with price-to-earnings (P/E) ratios of 48.79, 39.49, and 31.57 [4][5].

Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 10% following the announcement of a global licensing agreement for antibody molecules with BeiGene, indicating strong market confidence in the company's growth prospects and collaboration with established partners [1] Company Developments - Baiaosaitu has entered into a global licensing agreement with BeiGene, which includes an upfront payment and potential milestone payments based on development and commercialization, as well as royalties based on net sales [1] - The collaboration builds on an existing relationship where BeiGene had previously obtained a license for Baiaosaitu's RenMice fully human antibody platform, reflecting a deepening partnership [1] Financial Performance - Dongwu Securities reported that Baiaosaitu's operational performance in the first half of the year exceeded expectations, with significant growth in business development (BD) activities [1] - The company is expected to achieve over 40% growth in its antibody BD business and maintain over 40% growth in animal models, with preclinical CRO growth nearing 60%, leading to an overall revenue growth exceeding 40% [1]

Core Viewpoint - 百奥赛图-B (02315) has seen a significant increase in stock price following the announcement of a global licensing agreement with BeiGene for antibody molecules, indicating strong market confidence in the company's growth prospects [1] Group 1: Licensing Agreement - 百奥赛图 has entered into a global licensing agreement with BeiGene for antibody molecules, which includes an upfront payment and potential milestone payments based on development and commercialization [1] - The agreement builds on an existing collaboration where BeiGene had previously obtained a license for 百奥赛图's RenMice fully human antibody platform, indicating a deepening partnership [1] Group 2: Financial Performance - 东吴证券 reported that 百奥赛图's operating performance in the first half of the year exceeded expectations, with business development (BD) continuing to grow [1] - The company is expected to achieve over 40% growth in its antibody BD business in the first half of 2025, with animal models maintaining over 40% growth and preclinical CRO growth nearing 60% [1] - Overall revenue growth for 百奥赛图 is projected to exceed 40%, supported by a recovery in domestic industrial clients and a rapid increase in orders [1]